双氯西林诱导肠道P-糖蛋白但不增加DOAC使用者卒中/系统性栓塞风险
本研究通过随机交叉试验、体外实验和丹麦与英国注册数据库药物流行病学研究,评估双氯西林/氟氯西林对DOAC疗效的影响及机制。结果显示双氯西林增加肠道P-gp表达并降低达比加群口服吸收,但双氯西林/氟氯西林暴露未增加DOAC使用者卒中/系统性栓塞风险。
要点
- 双氯西林增加肠道P-gp表达,降低达比加群口服吸收(10天几何均值比0.67)。
- 双氯西林/氟氯西林与DOAC联用未增加卒中/系统性栓塞风险。
- 药物流行病学提示双氯西林/氟氯西林与DOAC间相互作用无临床影响。
核心结论
- 双氯西林增加肠道P-gp表达,导致达比加群口服吸收减少。
- 双氯西林/氟氯西林与DOAC联用未增加卒中/系统性栓塞风险,提示该药物相互作用无临床影响。
研究设计与样本
- 随机交叉研究评估双氯西林对P-gp底物口服吸收的影响(10天和28天治疗)。
- 体外使用LS174T细胞和原代人肝细胞3D球体研究双氯西林/氟氯西林对肠道和肝脏P-gp表达的影响。
- 基于丹麦全国健康登记和英国临床实践研究数据链,以苯氧甲基青霉素和阿莫西林为活性对照,估计DOAC使用者暴露于双氯西林/氟氯西林后卒中和系统性栓塞的风险比。
主要发现
- 双氯西林使达比加群AUC几何均值比在10天为0.67(95%CI:0.42-1.1),28天为0.72(95%CI:0.39-1.4)。
- 体外双氯西林增加肠道和肝脏细胞P-gp表达,氟氯西林仅影响肝脏细胞。
- 药物流行病学中,双氯西林与苯氧甲基青霉素相比卒中/系统性栓塞HR为0.93(95%CI:0.72-1.2)。
- 氟氯西林与阿莫西林相比卒中/系统性栓塞HR为0.89(95%CI:0.51-1.5)。
临床怎么用
- 双氯西林与达比加群联用时需关注P-gp介导的吸收降低,但当前证据未显示卒中/系统性栓塞风险增加。
- 双氯西林/氟氯西林与DOAC联用可能无需因该相互作用而调整抗凝方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We aimed to assess if dicloxacillin/flucloxacillin reduces the therapeutic efficacy of direct oral anticoagulants (DOACs) and the underlying molecular mechanism. METHODS: In a randomized, crossover study, we assessed whether dicloxacillin reduces oral absorption of drugs through P-glycoprotein (P-gp) during 10 and 28 days of treatment. To study the impact of dicloxacillin/flucloxacillin on intestinal and hepatic expression of P-gp in vitro, we usd LS174T cells and 3D spheroids of primary human hepatocytes. Finally, we used nationwide Danish health registries and the UK's Clinical Practice Research Datalink to estimate hazard ratios (HRs) for the risk of stroke and systemic embolism following dicloxacillin/flucloxacillin exposure among DOAC users, using phenoxymethylpenicillin and amoxicillin as active comparators. RESULTS: Dicloxacillin reduced the area under the curve of dabigatran to a geometric mean ratio 10 days of 0.67 (95% confidence interval [CI]: 0.42-1.1) and geometric mean ratio 28 days of 0.72 (95% CI: 0.39-1.4), suggesting reduced oral absorption via increased P-gp expression. In vitro, dicloxacillin raised P-gp expression in both intestinal and liver cells, while flucloxacillin only affected liver cells. In the pharmacoepidemiologic study, dicloxacillin and flucloxacillin were not associated with increased risk of stroke/systemic embolism (dicloxacillin vs. phenoxymethylpenicillin HR: 0.93, 95% CI: 0.72-1.2; flucloxacillin vs. amoxicillin HR: 0.89, 95% CI: 0.51-1.5). CONCLUSIONS: Dicloxacillin increases expression of intestinal P-gp, leading to reduced oral absorption of dabigatran. However, concomitant use of dicloxacillin/flucloxacillin was not associated with stroke and systemic embolism among DOAC users, suggesting no clinical impact from the drug-drug interaction between dicloxacillin/flucloxacillin and DOACs.
引用
- Iversen DB, Dunvald AD, Ernst MT, et al. Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users. Br J Clin Pharmacol. 2024. PMID: 39160000. doi:10.1111/bcp.16190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。